Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and Shammo
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
EP: 1.Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs
EP: 2.Looking at the Latest Data in Multiple Myeloma and Lymphoma From ASH 2023: Drs Landgren and Saeed
EP: 3.Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and Shammo
Today-
We are reporting from the 2023 ASH Annual Meeting!
Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Drs Kerry Rogers, Jennifer Brown, and Jamile Shammo to discuss some new data in chronic lymphocytic leukemia and myeloproliferative neoplasms.
Welcome to OncLive News Network! I’m Caroline Seymour.
Acalabrutinib (Calquence), as monotherapy or in combination with obinutuzumab (Gazyva), continued to improve progression-free survival (PFS) vs obinutuzumab and chemotherapy in patients with chronic lymphocytic leukemia (CLL), regardless of genomic marker status, according to 6-year follow-up data from the phase 3 ELEVATE-TN trial (NCT02475681).
The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta), at a duration determined by minimal residual disease (MRD), improved progression-free survival (PFS) and overall survival (OS) vs fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR) in patients with treatment-naive chronic lymphocytic leukemia (CLL), according to findings from the phase 3 FLAIR trial.
Pirtobrutinib (Jaypirca) continued to showcase clinically meaningful efficacy in heavily pretreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had prior exposure to a covalent BTK inhibitor, according to updated data from the phase 1/2 BRUIN study (NCT03740529).
Oral decitabine and cedazuridine and standard-of-care hypomethylating agents (HMAs) were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome (MDS), although improved treatment persistence was observed with oral decitabine and cedazuridine vs intravenous/subcutaneous HMAs beyond 6 months, according to findings from a retrospective study evaluating treatment patterns among real-world patients with MDS.
Please be sure to check out more of our coverage from the 2023 ASH Annual Meeting at OncLive.com.
Thank you for watching OncLive News Network: On Location, I’m Caroline Seymour.
